ZLCS is creeping back after disappointing FDA ruli

ZLCS is creeping back after disappointing FDA ruling but this is a rare find in the biotech community. They have funding and little debt, they have a income stream with approved drugs in the market place. .68 is cheap for ZLCS and I say we see this up start hit big in the coming months. This has buyout written all over it and even if it doesn't get bought out I see it headed back to $1.